Media headlines about Organovo (NASDAQ:ONVO) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Organovo earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 44.8706211579219 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- Organovo Holdings, Inc. (ONVO) stock price is showing notable negative signal for long-term investors on basis of 200 … (analystrecommendation.com)
- A quick recap Technical data on Organovo Holdings, Inc. (ONVO) (wallstreetmorning.com)
- Stock Performance in Focus: Organovo Holdings, Inc. (ONVO) (mostvolatilestocks.com)
- Global Bioprinting Market 2018 Outlook- Organovo HoldingInc, Cyfuse Biomedical, Luxexcel GroupBV and BioBots (factsweek.com)
- Global Non-Metal 3D Printing Market Share 2018 Organovo Holdings, Exone, 3D Systems and EnvisionTEC (themobileherald.com)
Separately, Zacks Investment Research raised Organovo from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a report on Thursday, March 8th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $3.40.
Organovo (NASDAQ:ONVO) last issued its quarterly earnings data on Thursday, February 8th. The medical research company reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. Organovo had a negative return on equity of 69.03% and a negative net margin of 881.93%. The company had revenue of $1.15 million during the quarter, compared to analyst estimates of $1.25 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. Organovo’s revenue was up .0% compared to the same quarter last year. research analysts anticipate that Organovo will post -0.33 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Organovo (NASDAQ:ONVO) Receiving Somewhat Positive News Coverage, Analysis Finds” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://stocknewstimes.com/2018/04/15/organovo-onvo-earning-somewhat-favorable-press-coverage-analysis-finds.html.
Organovo Holdings, Inc is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.